Financial Performance - Collegium reported Q2 2025 product revenues of $188.0 million, a 29% increase compared to $145.3 million in Q2 2024 [20] - Adjusted EBITDA for Q2 2025 was $105.1 million, a 9% increase compared to $96.0 million in Q2 2024 [20] - The company raised its 2025 financial guidance for net product revenues to a range of $745 million to $760 million, representing a 19% year-over-year change [47] - Adjusted EBITDA guidance was raised to a range of $440 million to $455 million, a 12% year-over-year increase [47] - Adjusted operating expenses guidance was raised to a range of $225 million to $235 million, a 53% year-over-year increase [47] Business Highlights - Q2 2025 saw a 23% year-over-year growth in prescriptions for the pain portfolio [20] - The company had $222.2 million in cash, cash equivalents, and marketable securities, up $59.4 million from December 2024 [20] - Collegium completed a $25 million Accelerated Share Repurchase (ASR) in July 2025 and has authorized a $150 million share repurchase program through December 2026 [20, 51] Jornay PM Performance & Strategy - Jornay PM revenue is expected to be between $140 million and $145 million in 2025, representing a 42% increase [36] - The company is investing in Jornay PM to support near-term growth and drive significant momentum in 2026 and beyond [37]